Uspeshnoe lechenie akromegalii Somatulinom: neyroendokrinnye i metabolicheskie aspekty

1. Вакс В.В. Диагностика и лечение акромегалии. // Лечащий врач 2004, 6,8-14.

2. Дедов И.И., Вакс В.В. Аналоги соматостатина в лечении опухолей нейроэндокринной системы. // Проблемы эндокринологии 2004, 6, 50,42-48.

3. Калинин А.В. Новое в онкогенезе, диагностике и лечении нейроэндокринных опухолей желудочно-кишечного тракта и поджелудочной железы. // Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 1998 (6), 13-17.

4. Марова Е.И., Пронин В.С., Агаджанян С.Э., Молитвословова Н.Н., Вакс В.В., Анциферов М.Б. Медико-социальные проблемы курации больных с акромегалией. // Consilium Medicum 2004, 6,9.

5. Altstadt T.J., Azzarelli B at al. Acromegaly caused by a growth hormone-releasing hormone-secreting carcinoid tumor. // Neurosergery 2002 50(6), 1356-9.

6. Attanasio R, Baldelli R, Pivonello R at al. Lanreotide 60 mg, a new long-acting for- mulation: effectiveness in the chronic treatment of acromegaly. // Clin Endocrinol Metab. 2003;88(11):5258-65.

7. Baldelli R, Battista C, Leonetti F at al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf). 2003;59(4):492-9.

8. Baldelli R, Durante C, D'Amico E at al. Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. // J Endocrinol Invest. 2003;26(12):1219-24.

9. Bondanelli M, Ambrosio MR, Zatelli MC at al. Regression of liver metastases of 49 occult carcinoid tumor with slow release lanreotide therapy.// World J Gastroenterol. 2005, 7;11(13):2041-4.

10. Colao A, Marzullo P, Lombardi G at al. Effect of a six-month treatment with lan- reotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. // Eur J Endocrinol. 2002 146(3):303-9.

11. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to deport somato- statin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. // Clin Endocrinol 2004, 61/2, 209-215.

12. Hofland LJ, Lamberts SW. Somatostatin receptors in pituitary function, diagnosis and therapy. // Front Horm Res. 2004;32:235-52.

13. Gutt B, Bidlingmaier M, Kretschmar K at al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).// Exp Clin Endocrinol Diabetes. 2005;113(3):139-44.

14. Ronchi CL, Orsi E, Giavoli C at al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. // J Endocrinol Invest. 2003; 26(6):533-8.

15. Vance ML, Laws ER Role of medical therapy in the management of acromegaly. // Neurosurgery 2005, 56(5): 877-85.

16. Weckbecker G., Lewis I., Albert R at al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. // Nature Reviews Drug Discovery 2003, 2, 12 999-1017.